ArticleAdvances in therapy2019

Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.

Noemi Muszbek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.